Apotex Manufacturing Violations Could Delay Launch of Taxotere Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warning letter cites continued violations of manufacturing regs; agency may put a hold on all pending drug applications.
You may also be interested in...
Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.